The World Health Organisation (WHO) estimates that more than one billion people worldwide are suffering from diseases of the Central Nervous System (CNS). MS is an inflammatory, demyelinating disease and the leading cause of non-traumatic neurological disability in young adults. MS is estimated to affect 2.3 million people worldwide; prevalence is particularly high in Europe and North America, with rates over 100 cases per 100,000.
Current standard therapies of MS include anti-inflammatory and symptomatic treatments. Although, relapse occurrence and duration are reduced by means of these therapies, no regeneration is achieved and there are no treatments for the progressive forms of MS. Therefore, MS is still a degenerative disease that leads to disability of patients in their most productive years.
